Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18268984 | 0.93 | ENPP2 (0.57) | ENPP2HDAC6SIGMAR1HDAC4HDAC1 | |
| SCHEMBL20201851 | 0.88 | ENPP2 (0.58) | ENPP2HDAC6HDAC4HDAC1HDAC2 | |
| SCHEMBL16750334 | 0.85 | ENPP2 (0.72) | ENPP2HDAC6HDAC4HDAC1HDAC2 | |
| SCHEMBL18268983 | 0.84 | ENPP2 (0.57) | ENPP2HDAC6HDAC4HDAC1HDAC2 | |
| SCHEMBL18070808 | 0.82 | ENPP2 (0.61) | ENPP2HDAC6HDAC4HDAC1HDAC2 | |
| SCHEMBL18269181 | 0.81 | ENPP2 (0.72) | ENPP2HDAC6SIGMAR1HDAC4HDAC1 | |
| SCHEMBL20201854 | 0.81 | ENPP2 (0.57) | ENPP2HDAC6SIGMAR1 | |
| SCHEMBL16750321 | 0.77 | ENPP2 (0.47) | ENPP2HDAC6HDAC4HDAC1HDAC2 | |
| SCHEMBL16750211 | 0.77 | ENPP2 (0.82) | ENPP2HDAC6HDAC4HDAC1HDAC2 | |
| SCHEMBL20201856 | 0.76 | ENPP2 (0.68) | ENPP2HDAC6HDAC4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147185-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147185-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885HDAC6 448/4885SIGMAR1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.